22.06.2022 DEINOVE- Third convening to an Extraordinary General Meeting on July 5, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
31.05.2022 DEINOVE - Adoption of all the ordinary resolutions at the Shareholders’ Meeting of May 30, 2022 The Extraordinary Shareholders’ Meeting will be convened on third notice on July 5, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French...
19.05.2022 DEINOVE- Second convening to a Combined General Meeting on May 30, 2022 DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
16.05.2022 DEINOVE reaches the first milestones of the Boost-ID project, selected as part of the France Relance plan, with the operational installation of its microfluidic screening platform The Boost-ID project was selected and financed under the France Relance plan The installation and qualification, in DEINOVE's premises in...
08.04.2022 DEINOVE presents its financial results and the advancement of its programs for 2021 Favorable opinion of the DSMB and continuation of the Phase II of of DNV3837 in the treatment of Clostridioides difficile infection ◦...
07.04.2022 The second part of the Phase II clinical trial of DNV3837 in Clostridioides difficile infections to be extended to Canada The extension of the clinical trial in Canada will add 5 new sites to those already active in the United States and accelerate patient...
23.03.2022 Issuance of a 4th tranche of €500,000 of notes convertibles into new shares DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...
17.03.2022 Michael MOUREZ joins the DEINOVE team as Chief Innovation Officer DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to...
02.03.2022 Thanks to the AGIR program, DEINOVE has become a unique French industrial biotech in the fight against antibiotic resistance The AGIR program, supported by the Investments for the Future Program, has allowed DEINOVE and the Charles Viollette Institute to develop...
26.01.2022 Issuance of 3rd tranche of €500,000 of notes convertibles into new shares DEINOVE strengthens its cash position to finance its working capital needs and the pursuance of the Phase II clinical trial evaluating...